Che Yueping, Shi Yan
Department of Pediatric Rehabilitation, The Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center For Child Health, Hangzhou, China.
Department of Children's Rehabilitation, The Third Affiliated Hospital of Zhejiang Chinese Medicine University, Hangzhou, China.
Transl Pediatr. 2022 May;11(5):757-765. doi: 10.21037/tp-22-171.
The study sought to construct a network of the effective components of traditional Chinese medicine (TCM) and potential therapeutic target genes of cerebral palsy based on data sets from high-throughput sequencing and the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP).
A transcriptome sequencing data set (GSE183021) of blood samples from children with cerebral palsy was downloaded from the Gene Expression Omnibus (GEO) database. The differentially expressed genes (DEGs) between the cerebral palsy blood samples and control blood samples were screened. The TCM active components and target genes were identified from the TCMSP. We constructed a network of the active ingredients of TCM and the cerebral palsy DEGs.
Using a |log2 fold change| ≥1 and a false discovery rate <0.05 as the screening criteria for the blood samples of 5 children with cerebral palsy and 5 control participants, 399 DEGs were identified. In the cerebral palsy blood samples, 209 genes were upregulated, and 190 genes were downregulated. The effective components of Angelica sinensis, Shenjincao, and Achyranthes bidentata, targeted 158 genes, and 49 genes crossed with the cerebral palsy DEGs. A network was constructed with the active ingredients of Angelica sinensis, Shenjincao, and Achyranthes bidentata and the DEGs of the cerebral palsy as nodes. () and had a wide range of effects on the effective components of Angelica sinensis, Shenjincao, and Achyranthes bidentata.
The effective components of Angelica sinensis, Shenjincao, Achyranthes sinensis, and interact closely with the cerebral palsy DEGs. Based on the interaction network, the pharmacological mechanism of TCM in the treatment of cerebral palsy can be elucidated and new therapeutic targets discovered.
本研究旨在基于高通量测序数据集以及中药系统药理学数据库与分析平台（TCMSP）构建中药有效成分与脑瘫潜在治疗靶基因的网络。
从基因表达综合数据库（GEO）下载脑瘫患儿血液样本的转录组测序数据集（GSE183021）。筛选脑瘫血液样本与对照血液样本之间的差异表达基因（DEGs）。从TCMSP中鉴定中药活性成分和靶基因。构建中药活性成分与脑瘫DEGs的网络。
以|log2倍数变化|≥1且错误发现率<0.05作为5名脑瘫患儿和5名对照参与者血液样本的筛选标准，共鉴定出399个DEGs。在脑瘫血液样本中，209个基因上调，190个基因下调。当归、伸筋草和牛膝的有效成分靶向158个基因，其中49个基因与脑瘫DEGs交叉。以当归、伸筋草和牛膝的活性成分以及脑瘫的DEGs为节点构建了一个网络。（）和对当归、伸筋草和牛膝的有效成分有广泛影响。
当归、伸筋草、牛膝的有效成分与脑瘫DEGs密切相互作用。基于该相互作用网络，可以阐明中药治疗脑瘫的药理机制并发现新的治疗靶点。
